Aquila European Renewables (AERI) Share Price, News & Analysis

Company Overview

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.

Key Stats

• Today's Range: 0.66 to 0.67
• 50-Day Range: 0.65 to 0.68
• 52-Week Range: 0.62 to 0.84
• Volume: 208,707 shs
• Average Volume: 594,779 shs
• Market Capitalization: £2.53 million
• P/E Ratio: 22.30
• Dividend Yield: 747.38%
• Price Target: N/A
• Consensus Rating: N/A

AERI Stock Analysis - Frequently Asked Questions

How have AERI shares performed this year?

Aquila European Renewables' stock was trading at GBX 0.79 at the beginning of 2024. Since then, AERI stock has decreased by 14.8% and is now trading at GBX 0.67.
View the best growth stocks for 2024 here.

How do I buy shares of Aquila European Renewables?

Shares of AERI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Manufacturing
• Industry: Biological Product (Except Diagnostic) Manufacturing
• Sub-Industry: N/A
• Current Symbol: LON:AERI
• CUSIP: N/A
• CIK: N/A
• Web: www.aquila-european-renewables-income-fund.com
• Phone: 19192375300
• Fax: N/A
• Employees: 365
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 22.30
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 378,120,000
• Free Float: N/A
• Market Cap: £2.53 million
• Optionable: Not Optionable
• Beta: N/A